Jun. 28 at 10:20 PM
$IOVA
The thesis keeps getting stronger:
• FDA-approved first TIL therapy for solid tumors (Amtagvi)
• Australia became the 3rd country to approve Amtagvi
• Q1 revenue:
$71.4M (+45% YoY)
• FY2026 guidance:
$350–370M
• Cash runway projected into 2028
• FDA cleared IND for next-generation IOV-5001 (2H26 trial start)
Clinical data:
• Mayo real-world melanoma: 55.6% ORR, 77.8% disease control
• Long-term survivor modeling suggests ~50% of responders may become long-term survivors
• NSCLC previously reported: 26% ORR, 2 complete responses, median duration of response still not reached after 25+ months
• Frontline NSCLC combo previously reported: 64.3% ORR in an early cohort
• Early sarcoma data: 50% confirmed ORR in the first evaluable patients
The science keeps advancing.
The commercial launch keeps expanding.
The next major catalyst remains updated NSCLC data.
